Moderna has formally requested emergency use authorization for its coronavirus vaccine from the Food and Drug Administration. The company reported that the vaccine is 94.1% at preventing symptomatic COVID-19. (Endpoints News)

Amgen, UCB and Takeda Pharmaceuticals are partnering on a trial to determine whether three different drugs can reduce COVID-19 severity by modulating the immune system’s response to it. The trial will test the benefits of Amgen’s Otezla, a psoriasis treatment; Takeda’s lanadelumab, an anti-inflammatory; and UCB’s zilucoplan, an immune system inhibitor. (Reuters)

The Food and Drug Administration has ended a much-criticized program that requires drugmakers to secure regulatory approval for products already on the market. Launched in 2006, the Unapproved Drugs Initiative was designed to accumulate data on medicines that arrived on the market before stricter approval requirements were put into place. (STAT)

In the wake of the long Thanksgiving weekend, many Americans are facing strict new measures designed to limit the spread of COVID-19. Los Angeles County, home to 10 million people, has imposed a stay-at-home order. (Associated Press)

The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention is convening on Tuesday to set up a framework around who will receive the first COVID-19 vaccine shots. The Committee plans to tackle the thorny question of whether prisoners and other detainees should be among the first to get them. (The New York Times)